Why the study?
Whether patients with atrial fibrillation at the high-end of renal function feature reduced drug plasma levels and/or reduced efficacy with NOACs is not well established.
Do non-vitamin K antagonist oral anticoagulants have reduced efficacy or plasma levels in patients with atrial fibrillation and glomerular hyperfiltration?
Do non-vitamin K antagonist oral anticoagulants have reduced efficacy or plasma levels in patients with atrial fibrillation and glomerular hyperfiltration?
There is currently no firm evidence to suggest that NOACs have reduced efficacy in atrial fibrillation patients with glomerular hyperfiltration.
Answers are grounded in this paper and cite their sources.
Supports standard NOAC dosing in AF with hyperfiltration; leaves open dedicated PK studies in this population.
Non-vitamin K antagonist oral anticoagulants (NOACs) are significantly excreted through the kidneys. Patients with reduced renal function feature increased plasma levels and, as such, are prescribed reduced dosage regimens. Patients with ‘normal’ renal function receive conventional dosage regimens. On the other hand, whether patients at the high-end of renal function feature reduced drug plasma levels and/or reduced efficacy is not well established. Should clinicians be concerned on the clinical efficacy of NOACs in such patients? Following a systematic review of the literature we did not find firm evidence for reduced efficacy and/or plasma levels of NOACs in hyperfiltration patients. Previous signals may have been secondary to spurious low event rates in the subset of hyperfiltrating patients receiving vitamin K antagonists. GFR, glomerular filtration rate; HR, hazard ratio; RCT, randomized control trial; SEE, systemic embolic event.
No takes yet. Share an insight, caveat, or question.
Huqi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: